Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer.
10.3760/cma.j.cn112152-20220521-00360
- Collective Name:Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association;;International Medical Exchange Society, Chinese Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
Adverse drug reaction;
Antibody-drug conjugate;
Breast neoplasms;
Consensus
- MeSH:
Ado-Trastuzumab Emtansine/therapeutic use*;
Antibodies, Monoclonal/therapeutic use*;
Antineoplastic Agents, Immunological/therapeutic use*;
Breast Neoplasms/therapy*;
Camptothecin/adverse effects*;
Consensus;
Cytotoxins/therapeutic use*;
Female;
Humans;
Immunoconjugates/therapeutic use*;
Neutropenia/etiology*;
Receptor, ErbB-2/metabolism*;
Trastuzumab/therapeutic use*;
Triple Negative Breast Neoplasms/therapy*;
Ventricular Function, Left
- From:
Chinese Journal of Oncology
2022;44(9):913-927
- CountryChina
- Language:Chinese
-
Abstract:
As a newly emerged class of anticancer bioagents in the most precise and selectively targeted way, antibody-drug conjugate (ADC) combines the cancer-targeting abilities of monoclonal antibodies with the cytotoxicity potency of payload, delivering highly cytotoxic drug into tumors via 'targeted chemotherapy'. ADC has revolutionized the treatment landscape of human epidermal growth factor receptor 2 positive and triple negative subtypes in breast cancer. Three ADCs have been approved by U. S. Food and Drug Administration with breast cancer indications, including trastuzumab emtansine (T-DM1; also approved in China), trastuzumab deruxtecan (T-DXd, DS-8201) and sacituzumab govitecan (IMMU-132; also approved in China). Antibodies, cytotoxic drug, linker, and conjugation process are implicated in ADC profile, resulting in unique adverse drug reactions and toxicity heterogeneity within ADC class. For example, more attention should be paid to the management of thrombocytopenia, hepatotoxicity, and reductions in left ventricular ejection fraction (LVEF) in patients treated with trastuzumab emtansine; clinical physicians should pay attention to the risk of neutropenia, interstitial lung disease/pneumonitis, and reductions in LVEF when treated with trastuzumab deruxtecan; sacituzumab govitecan most frequently caused neutropenia, anemia and diarrhea requiring close monitor. ADC has generally favorable safety profiles, and dose modifications and/or symptomatic supporting treatment are effective in terms of toxicity management. This consensus aims at providing guidance for clinical oncologists of early detection, regular assessment, timely management and follow-up monitor of ADC-associated adverse reactions/events.
